Literature DB >> 12707735

On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma.

D Ribatti, A Vacca.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12707735     DOI： 10.1007/s00277-003-0622-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  1 in total

1.  Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.

Authors:  George Somlo; Ashkan Lashkari; William Bellamy; Todd M Zimmerman; Joseph M Tuscano; Margaret R O'Donnell; Ann F Mohrbacher; Stephen J Forman; Paul Frankel; Helen X Chen; James H Doroshow; David R Gandara
Journal:  Br J Haematol       Date:  2011-04-26       Impact factor: 6.998
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.